Among the breast cancer subtypes, TNBC is the most aggressive, has a poor prognosis and a high risk of recurrence and metastasis (4–6), and complicates targeted therapies in patients due to the absence of hormonal receptors (ER, PR, HER2) (6). Here, ERBB2 is linked to breast carcinoma.